You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Summary of Model Parameters (including uncertainty at 95% confidence intervals)

From: Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients

Parameter Value Source
Mean number of patients in PAC per year (from 2009 to 2013) 5688 [11]
Number of patients at high risk of VTE 3583 [11]
Annual cost of new model of care Model 1 (existing pharmacy service) $20,989 [11, 17]
Annual cost of new model of care Model 2 (new pharmacy service) $154,579 - $12,741 = $141,838 [11, 17]
Appropriateness of VTE prophylaxis new model of care (%) 100 (SE 0.01) [11]
Appropriateness of VTE prophylaxis usual care (%) 91.1 (84.7–97.3) [11]
Probability of DVT with appropriate prophylaxis (%) 1.6 (0.9–2.3) [11]
Probability of DVT with inappropriate prophylaxis (%) 4.0 (2.7–5.3) [11]
Probability of PE with appropriate prophylaxis (%) 1.1 (0.7–1.5) [11]
Probability of PE with inappropriate prophylaxis (%) 2.7 (1.9–3.3) [11]
Probability of 12 months mortality post DVT (%) 14.6 (14.0–15.2) [11]
Probability of 12 month mortality post PE (%) 52.3 (51.5–53.1) [11]
Probability of 30 day mortality post DVT (%) 5.5 (5.1–5.9) [11]
Probability of 30 day mortality post PE (%) 44.4 (43.6–45.2) [11]
Direct cost to healthcare system of one episode of acute DVT $10,077 [2]
Direct cost to healthcare system of one episode of acute PE $10,042 [2]
QALYs lost post-acute episode of DVT 0.02 (0.01–0.04) [16]
QALYs lost post-acute episode of PE 0.02 (0.01–0.05) [16]
QALYs lost post-acute episode of DVT + 30 day death 0.0675 () [16]
QALYs lost post-acute episode of PE + 30 day death 0.0625 () [16]